Recommendations of the Latin American Thyroid Society on diagnosis and management of differentiated thyroid cancer

Harach HR, 2008, Thyroid cancer, thyroiditis and dietary iodine: a review based on the Salta, Argentina model, Endocr Pathol., 19, 209, 10.1007/s12022-008-9038-y

Pretell EA, 2004, Iodine nutrition improves in Latin America, Thyroid., 14, 595, 10.1089/1050725041692909

Davies L, 2006, Increasing incidence of thyroid cancer in the United States, 1973-2002, JAMA., 295, 2164, 10.1001/jama.295.18.2164

Harach HR, 1985, Occult papillary carcinoma of the thyroid, A "normal" finding in Finland. A systematic autopsy study. Cancer., 56, 531

Sobrinho-Simoes M, 2004, Follicular carcinoma, 67

Foulkees WD, 2004, Familial non-medullary thyroid cancer, 257

Gauna A, 2006, Consenso argentino de carcinoma diferenciado de tiroides, Rev Arg Endocrinol Metab., 43, 131

Maia AL, 2007, Thyroid nodules and differentiated thyroid cancer: Brazilian consensus, Arq Bras Endocrinol Metabol., 51, 867

Hundahl SA, 1998, A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U, S., 1985-1995. Cancer., 83, 2638

Deveci MS, 2007, Concordance between thyroid nodule sizes measured by ultrasound and gross pathology examination: effect on patient management, Diagn Cytopathol., 35, 579, 10.1002/dc.20714

Mathias-Guiu X, 2004, Medullary carcinoma, 86

Farkas EA, 2002, A comparison of total thyroidectomy and lobectomy in the treatment of dominant thyroid nodules, Am Surg., 68, 678, 10.1177/000313480206800805

Hay ID, 2002, Managing patients with papillary thyroid carcinoma: insights gained from the Mayo Clinic's experience of treating 2,512 consecutive patients during 1940 through 2000, Trans Am Clin Climatol Assoc., 113, 241

Appetecchia M, 2002, Outcome after treatment of papillary thyroid microcarcinoma, J Exp Clin Cancer Res., 21, 159

Bonnin C, 1997, Outcome of 111 thyroid papillary carcinomas, Retrospective study from 1953 to 1994. Experience of Bergonie Institute. Ann Endocrinol (Paris)., 58, 318

Satge D, 1990, [Thyroid microcarcinoma with a fatal outcome and 34 other unusually aggressive cases reported in the literature], Arch Anat Cytol Pathol., 38, 143

Robbins KT, 2002, Neck dissection classification update: revisions proposed by the American Head and Neck Society and the American Academy of Otolaryngology-Head and Neck Surgery, Arch Otolaryngol Head Neck Surg., 128, 751, 10.1001/archotol.128.7.751

Shaha AR, 2008, Complications of neck dissection for thyroid cancer, Ann Surg Oncol., 15, 397, 10.1245/s10434-007-9724-x

Loh KC, 1997, Pathological tumor-node-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients, J Clin Endocrinol Metab., 82, 3553, 10.1210/jcem.82.11.4373

Mazzaferri EL, 1994, Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer, Am J Med., 97, 418, 10.1016/0002-9343(94)90321-2

Samaan NA, 1992, The results of various modalities of treatment of well differentiated thyroid carcinomas: A retrospective review of 1599 patients, J Clin Endocrinol Metab., 75, 714

Sawka AM, 2004, Clinical review 170: A systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer, J Clin Endocrinol Metab., 89, 3668, 10.1210/jc.2003-031167

Pellegriti G, 2004, Clinical behavior and outcome of papillary thyroid cancers smaller than 1, 5 cm in diameter: study of 299 cases. J Clin Endocrinol Metab., 89, 3713

Lakshmanan M, 1988, A simplified low iodine diet in I-131 scanning and therapy of thyroid cancer, Clin Nucl Med., 13, 866, 10.1097/00003072-198812000-00003

Park HM, 1991, Influence of diagnostic radioiodines on the uptake of ablative dose of iodine-131, Thyroid., 4, 49, 10.1089/thy.1994.4.49

Jeevanram RK, 1986, Influence of initial large dose on subsequent uptake of therapeutic radioiodine in thyroid cancer patient, Int J Rad Appl Instrum B., 13, 277, 10.1016/0883-2897(86)90108-X

Rosario PW, 2004, Efficacy of low and high 131I doses for thyroid remnant ablation in patients with differentiated thyroid carcinoma based on post-operative cervical uptake, Nucl Med Commun., 25, 1077, 10.1097/00006231-200411000-00002

Bal C, 1996, Prospective randomized clinical trial to evaluate the optimal dose of 131 I for remnant ablation in patients with differentiated thyroid carcinoma, Cancer., 77, 2574, 10.1002/(SICI)1097-0142(19960615)77:12<2574::AID-CNCR22>3.0.CO;2-O

Johansen K, 1991, Comparison of 1073 MBq and 3700 MBq iodine-131 in postoperative ablation of residual thyroid tissue in patients with differentiated thyroid cancer, J Nucl Med., 32, 252

Ward LS, 2009, High-dose radioiodine outpatient therapy, Arq Bras Endocrinol Metabol., 53, 301, 10.1590/S0004-27302009000300001

Pacini F, 2006, Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study, J Clin Endocrinol Metab., 91, 926, 10.1210/jc.2005-1651

Tuttle RM, 2008, Recombinant human TSH-assisted radioactive iodine remnant ablation achieves short-term clinical recurrence rates similar to those of traditional thyroid hormone withdrawal, J Nucl Med., 49, 764, 10.2967/jnumed.107.049072

Pilli T, 2007, A comparison of 1850 (50 mCi) and 3700 MBq (100 mCi) 131-iodine administered doses for recombinant thyrotropin-stimulated postoperative thyroid remnant ablation in differentiated thyroid cancer, J Clin Endocrinol Metab., 92, 3542, 10.1210/jc.2007-0225

Chianelli M, 2009, Low-activity (2. 0 GBq; 54 mCi) radioiodine post-surgical remnant ablation in thyroid cancer: between hormone withdrawal and use of rhTSH in low-risk patients, Eur J Endocrinol., 160, 431, 10.1530/EJE-08-0669

Hänscheid H, 2006, Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal, J Nucl Med., 47, 648

Rosário PW, 2008, Preparation with recombinant human thyroid-stimulating hormone for thyroid remnant ablation with 131I is associated with lowered radiotoxicity, J Nucl Med., 49, 1776, 10.2967/jnumed.108.050591

Fatourechi V, 2000, Are posttherapy radioiodine scans informative and do they influence subsequent therapy of patients with differentiated thyroid cancer?, Thyroid., 10, 573, 10.1089/thy.2000.10.573

Pujol P, 1996, Degree of thyrotropin suppression as a prognostic determinant in differentiated thyroid cancer, J Clin Endocrinol Metab., 81, 4318

Parle JV, 2001, Prediction of all-cause and cardiovascular mortality in elderly people from one low serum thyrotropin result: a 10-year cohort study, Lancet., 358, 861, 10.1016/S0140-6736(01)06067-6

Ronga G, 1999, Value of the first serum thyroglobulin level after total thyroidectomy for the diagnosis of metastases from differentiated thyroid carcinoma, Eur J Nucl Med., 26, 1448, 10.1007/s002590050477

Heemstra KA, 2007, Serum thyroglobulin concentrations predict disease-free remission and death in differentiated thyroid carcinoma, Clin Endocrinol (Oxf)., 66, 58, 10.1111/j.1365-2265.2006.02685.x

Spencer CA, 1998, Serum thyroglobulin autoantibodies: prevalence, influence on serum thyroglobulin measurement, and prognostic significance in patients with differentiated thyroid carcinoma, J Clin Endocrinol Metab., 83, 1121

Haugen BR, 2002, Clinical comparison of whole-body radioiodine scan and serum thyroglobulin after stimulation with recombinant human thyrotropin, Thyroid., 12, 37, 10.1089/105072502753451959

Cailleux AF, 2000, Is diagnostic iodine-131 scanning useful after total thyroid ablation for differentiated thyroid cancer?, J Clin Endocrinol Metab., 85, 175, 10.1210/jcem.85.1.6310

David A, 2005, Clinical value of different responses of serum thyroglobulin to recombinant human thyrotropin in the follow-up of patients with differentiated thyroid carcinoma, Thyroid., 15, 267, 10.1089/thy.2005.15.267

Baudin E, 2003, Positive predictive value of serum thyroglobulin levels, measured during the first year of follow-up after thyroid hormone withdrawal, in thyroid cancer patients, J Clin Endocrinol Metab., 88, 1107, 10.1210/jc.2002-021365

Spencer CA, 2005, Clinical impact of thyroglobulin (Tg) and Tg autoantibody method differences on the management of patients with differentiated thyroid carcinomas, J Clin Endocrinol Metab., 90, 5566, 10.1210/jc.2005-0671

Pacini F, 2003, Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma, J Clin Endocrinol Metab., 88, 3668, 10.1210/jc.2002-021925

Leboulleux S, 2007, Ultrasound criteria of malignancy for cervical lymph nodes in patients followed up for differentiated thyroid cancer, J Clin Endocrinol Metab., 92, 3590, 10.1210/jc.2007-0444

Liel Y, 2002, Preparation for radioactive iodine administration in differentiated thyroid cancer patients, Clin Endocrinol (Oxf)., 57, 523, 10.1046/j.1365-2265.2002.01631.x

Golger A, 2003, Three-week thyroxine withdrawal thyroglobulin stimulation screening test to detect low-risk residual/recurrent well-differentiated thyroid carcinoma, J Endocrinol Invest., 26, 1023, 10.1007/BF03348202

Haugen BR, 1999, A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer, J Clin Endocrinol Metab., 84, 3877

Helal BO, 2001, Clinical impact of (18)F-FDG PET in thyroid carcinoma patients with elevated thyroglobulin levels and negative (131)I scanning results after therapy, J Nucl Med., 42, 1464

Chin BB, 2004, Recombinant human thyrotropin stimulation of fluoro-D-glucose positron emission tomography uptake in well-differentiated thyroid carcinoma, J Clin Endocrinol Metab., 89, 91, 10.1210/jc.2003-031027

Schlumberger M, 1997, 131I therapy for elevated thyroglobulin levels, Thyroid., 7, 273, 10.1089/thy.1997.7.273

Schlumberger M, 1986, Long-term results of treatment of 283 patients with lung and bone metastases from differentiated thyroid carcinoma, J Clin Endocrinol Metab., 63, 960, 10.1210/jcem-63-4-960

Schlumberger M, 2007, Comparison of seven serum thyroglobulin assays in the follow-up of papillary and follicular thyroid cancer patients, J Clin Endocrinol Metab., 92, 2487, 10.1210/jc.2006-0723

Smallridge RC, 2007, Monitoring thyroglobulin in a sensitive immunoassay has comparable sensitivity to recombinant human tsh-stimulated thyroglobulin in follow-up of thyroid cancer patients, J Clin Endocrinol Metab., 92, 82, 10.1210/jc.2006-0993

Maciel RM., 2007, [Will the thyroglobulin assay with lower functional sensitivity whilst the patients are on L-T4 treatment replace the TSH-stimulated thyroglobulin assay in the follow-up of patients with differentiated thyroid cancer?], Arq Bras Endocrinol Metabol., 51, 862

de Keizer B, 2003, Tumour dosimetry and response in patients with metastatic differentiated thyroid cancer using recombinant human thyrotropin before radioiodine therapy, Eur J Nucl Med Mol Imaging., 30, 367, 10.1007/s00259-002-1076-y

Pitoia F, 2006, Usefulness of recombinant human TSH aided radioiodine doses administered in patients with differentiated thyroid carcinoma, Medicina (B Aires)., 66, 125

Luster M, 2005, rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review, Endocr Relat Cancer., 12, 49, 10.1677/erc.1.00830

Jentzen W, 2008, Optimized 124I PET dosimetry protocol for radioiodine therapy of differentiated thyroid cancer, J Nucl Med., 49, 1017, 10.2967/jnumed.107.047159

Koong SS, 1999, Lithium as a potential adjuvant to 131I therapy of metastatic, well differentiated thyroid carcinoma, J Clin Endocrinol Metab., 84, 912

Shimaoka K, 1985, A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma, Cancer., 56, 2155, 10.1002/1097-0142(19851101)56:9<2155::AID-CNCR2820560903>3.0.CO;2-E

Pennell NA, 2008, A phase II study of gefitinib in patients with advanced thyroid cancer, Thyroid., 18, 317, 10.1089/thy.2007.0120

Sherman SI, 2008, Motesanib Cancer Study Group, Motesanib Diphosphate in progressive differentiated thyroid cancer. N Engl J Med., 3, 31

Gupta-Abramson V, 2008, Phase II trial of sorafenib in advanced thyroid cancer, J Clin Oncol., 26, 4714, 10.1200/JCO.2008.16.3279

Cohen EE, 2008, Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study, J Clin Oncol., 26, 4708, 10.1200/JCO.2007.15.9566

Ain KB, 2007, Phase II trial of thalidomide for therapy of radiodine-unresponsive and rapidly progressive thyroid carcinomas, Thyroid., 17, 663, 10.1089/thy.2006.0289

Hung W, 2002, Current controversies in the management of pediatric patients with well-differentiated nonmedullary thyroid cancer: a review, Thyroid., 12, 683, 10.1089/105072502760258668

Iorcansky S, 2005, Serum thyrotropin (TSH) levels after recombinant human TSH injections in children and teenagers with papillary thyroid cancer, J Clin Endocrinol Metab., 90, 6553, 10.1210/jc.2005-1550

Vini L, 1999, Management of differentiated thyroid cancer diagnosed during pregnancy, Eur J Endocrinol., 140, 404, 10.1530/eje.0.1400404